60 Degrees Pharmaceuticals Reports PCR-Negative Outcomes in Five Patients
The company said all five completed patients in its expanded access study showed clinical improvement and tested negative for Babesia by conventional PCR; four of five were NAT-negative after treatment. It may pursue accelerated approval using NAT nonreactivity as a surrogate.